The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

OMCL

Omnicell, Inc.

Healthcare · Medical - Equipment & Services

Overall research band Very weak
Quality Very weak
Valuation Mixed
Balance sheet Very weak
Market confirmation Very weak

One-minute company read

What this report can tell you now

What the company does

Omnicell, Inc. provides healthcare technology solutions in the United States and internationally, focusing on automating and optimizing medication management for hospitals, health systems, and pharmacies. Its main products and services include automated dispensing systems like Titan XT and XTExtend, Central Pharmacy Dispensing and Med Automation Services, IV Compounding Service, and specialty pharmacy solutions. Omnicell also offers the EnlivenHealth platform for retail and community pharmacies, medication adherence solutions, and the OmniSphere cloud-based platform. The company generates revenue through the sale of hardware and software products, consumables, professional services such as technology implementation and training, and ongoing support and maintenance.

The current research profile is Mixed Setup, with elevated leverage. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

No single strength should be treated as decisive without reviewing the underlying evidence and data status.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC2.2%Model input; read with the evidence status and period context.
Operating margin2.8%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years1.1%Model input; read with the evidence status and period context.
FCF margin9.1%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.